BTN3A1

Official Full Name

butyrophilin subfamily 3 member A1

Organism

Homo sapiens

GeneID

11119

Background

The butyrophilin (BTN) genes are a group of major histocompatibility complex (MHC)-associated genes that encode type I membrane proteins with 2 extracellular immunoglobulin (Ig) domains and an intracellular B30.2 (PRYSPRY) domain. Three subfamilies of human BTN genes are located in the MHC class I region: the single-copy BTN1A1 gene (MIM 601610) and the BTN2 (e.g., BTN2A1; MIM 613590) and BTN3 (e.g., BNT3A1) genes, which have undergone tandem duplication, resulting in 3 copies of each (summary by Smith et al., 2010 [PubMed 20208008]).[supplied by OMIM, Nov 2010]

Synonyms

BTF5; BT3.1; CD277; BTN3.1;

Cat.No.	Product Name	Price

Cat.No.	Product Name	Price

Cat.No.	Product Name	Price

Cat.No.	Product Name	Price

Detailed Information

The BTN3A1 gene encodes Butyrophilin Subfamily 3 Member A1 and is located on human chromosome 6p22.2. This region resides within the Major Histocompatibility Complex (MHC) class I gene locus and is closely linked to numerous immune-related genes. BTN3A1 belongs to the butyrophilin protein family, members of which share common structural features: they are type I transmembrane proteins comprising an extracellular segment with two immunoglobulin-like domains and an intracellular segment that terminates with a B30.2 domain. BTN3A1 is not isolated but forms a gene cluster within the MHC region alongside its paralogs, BTN3A2 and BTN3A3. This tandemly repeated evolutionary pattern suggests that the family has undergone functional diversification and specialization. Structurally, BTN3A1 exhibits a degree of similarity to MHC class I molecules and the B7 co-stimulatory molecule family, hinting at a potential role in immune recognition and regulation, although its precise function remained an immunological enigma for a long time.

Biological Significance

BTN3A1 plays a critical role as a sensor of intracellular phosphorylated metabolites, acting as a bridge between cellular metabolic status and the immune surveillance function of γδ T cells. γδ T cells are a unique T-cell subset positioned between innate and adaptive immunity. They do not rely on classical MHC molecules for antigen presentation but can rapidly respond to infected or transformed cells. The breakthrough in BTN3A1 research was the identification of BTN3A1 as an essential ligand-presenting molecule for γδ T-cell receptor (TCR) activation, operating via a highly distinctive mechanism. When intracellular levels of phosphorylated metabolites-particularly isopentenyl pyrophosphate (IPP) and (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate (HMBPP)-accumulate due to infection or malignant transformation, these metabolites bind directly to a specific pocket within the intracellular B30.2 domain of BTN3A1.

Figure 1. Domain organization and dimerization state of the BTN3A family members. (Castro CD, et al., 2020)

This binding triggers significant conformational changes in BTN3A1, which are transmitted through its transmembrane region, resulting in a rearrangement of the extracellular domain to form a "ligand" epitope recognized by specific γδ T-cell subpopulations. In essence, BTN3A1 does not act as a traditional ligand; rather, it functions as a molecular transducer that converts intracellular "danger signals" into cell surface cues that can be recognized by γδ T cells. This mechanism allows the immune system to bypass the need for complex pathogen- or tumor-specific antigen recognition, instead detecting "problem cells" by monitoring metabolic anomalies.

Figure 2. BTN3A1 Molecular Analysis and Models of Membrane Reorganization upon pAg binding. (Castro CD, et al., 2020)

Beyond its central role in γδ T-cell activation, BTN3A1 also contributes to broader immune regulation. Studies show it can modulate conventional αβ T-cell activation by suppressing proliferation and cytokine production, suggesting a potential immune checkpoint function that is context-dependent, influenced by cell type, microenvironment, and interactions with other co-stimulatory or inhibitory molecules. BTN3A1 thus represents a novel class of immune modulators that finely tune T-cell-mediated immune responses through sensing intracellular metabolic states.

Clinical Relevance

The translational potential of BTN3A1 is mainly in cancer immunotherapy, particularly in strategies targeting γδ T cells. Leveraging BTN3A1's phosphoantigen-sensing mechanism, developing agonists that mimic or enhance this pathway has emerged as a promising approach to activate endogenous γδ T cells for tumor eradication. For example, aminobisphosphonates (e.g., pamidronate, zoledronate), widely used clinically for osteoporosis and bone metastases, have been found to inhibit the mevalonate pathway, leading to intracellular accumulation of IPP and subsequent γδ T-cell activation via BTN3A1. This repurposes existing drugs as potential anticancer immunomodulators.

Additionally, agonistic antibodies targeting BTN3A1's extracellular domain are under active development. These antibodies can directly mimic the conformational changes induced by phosphoantigens, bypassing the need for intracellular metabolite accumulation, thereby activating γδ T cells more directly and potently. Preclinical studies show strong antitumor activity, and early-phase clinical trials are underway for both hematologic malignancies and solid tumors.

Challenges remain. First, understanding the functional differences among BTN3A1 isoforms is critical for ensuring therapeutic specificity and efficacy. Second, avoiding systemic inflammation or cytokine storms from excessive activation is a key safety consideration. Mapping BTN3A1 expression patterns across tumor types and their correlation with treatment response is crucial for patient stratification. Beyond agonists, in certain contexts, blocking BTN3A1's inhibitory effects on αβ T cells may also enhance antitumor immunity. In autoimmune and inflammatory diseases, although still at an early stage, BTN3A1's potential as an immune checkpoint suggests a role in maintaining self-tolerance, with dysregulation potentially contributing to disease, providing a novel therapeutic target.

In summary, BTN3A1, as a pivotal link between cellular metabolism and immune recognition, opens a promising avenue for the development of next-generation immunotherapies. Its full clinical potential will depend on further elucidation of the precise molecular mechanisms governing its activity.

References

Vavassori S, Kumar A, Wan GS, et al. Butyrophilin 3A1 binds phosphorylated antigens and stimulates human γδ T cells. Nat Immunol. 2013;14(9):908-916.
Sandstrom A, Peigné CM, Léger A, et al. The intracellular B30.2 domain of butyrophilin 3A1 binds phosphoantigens to mediate activation of human Vγ9Vδ2 T cells. Immunity. 2014;40(4):490-500.
Castro CD, Boughter CT, Broughton AE, Ramesh A, Adams EJ. Diversity in recognition and function of human γδ T cells. Immunol Rev. 2020 Nov;298(1):134-152.
Burke KP, Chaudhri A, Freeman GJ, Sharpe AH. The B7:CD28 family and friends: Unraveling coinhibitory interactions. Immunity. 2024 Feb 13;57(2):223-244.

Quick Inquiry

Interested in learning more?

Contact us today for a free consultation with the scientific team and discover how Creative Biogene can be a valuable resource and partner for your organization.

Request a quote today!

Inquiry